Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment
Drug Delivery and Translational Research · 2025
DOI: 10.1007/s13346-024-01589-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Drug Delivery and Translational Research, 2025. Verfasst von Fathima Paleel und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Pharmacy, Queen's University Belfast, BT9 7BL, Belfast, UK. Hauptthemen laut MEDLINE: Timolol, Printing, Three-Dimensional, Delayed-Action Preparations, Glaucoma. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Medical Research Council.
Abstract (Originalsprache)
Timolol maleate (TML) is a beta-blocker drug that is commonly used to lower the intraocular pressure in glaucoma. This study focused on using a 3D printing (3DP) method for the manufacturing of an ocular, implantable, sustained-release drug delivery system (DDS). Polycaprolactone (PCL), and PCL with 5 or 10% TML implants were manufactured using a one-step 3DP process. Their physicochemical characteristics were analysed using light microscopy, scanning electronic microscopy (SEM), differential scanning calorimetry (DSC) / thermal gravimetric analysis (TGA), and Fourier-transform infrared spectroscopy (FTIR). The in vitro drug release was evaluated by UV-spectrophotometry. Finally, the effect of the implants on cell viability in human trabecular meshwork cells was assessed. All the implants showed a smooth surface. Thermal analysis demonstrated that the implants remained thermally stable at the temperatures used for the printing, and FTIR studies showed that there were no significant interactions between PCL and TML. Both concentrations (5 & 10%) of TML achieved sustained release from the implants over the 8-week study period. All implants were non-cytotoxic to human trabecular cells. This study shows proof of concept that 3DP can be used to print biocompatible and personalised ocular implantable sustained-release DDSs for the treatment of glaucoma. Graphical Abstract
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Pharmacy, Queen's University Belfast, BT9 7BL, Belfast, UK.
- Faculty of Life Sciences & Medicine, King's College London, SE1 7EH, London, UK.
- Department of Biology, Edge Hill University, L39 4QP, Ormskirk, UK.
- Faculty of Life Sciences & Medicine, King's College London, SE1 7EH, London, UK. cynthia.yu-wai-man@kcl.ac.uk.
- School of Pharmacy, Queen's University Belfast, BT9 7BL, Belfast, UK. d.lamprou@qub.ac.uk.
ORCID-Profile: Dimitrios A Lamprou
Förderung
- Medical Research Council
Zitieren
APA
Paleel, F., Qin, M., Tagalakis, A. D., Yu-Wai-Man, C., & Lamprou, D. A. (2025). Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment. Drug Delivery and Translational Research. https://doi.org/10.1007/s13346-024-01589-8
Vancouver
Paleel F, Qin M, Tagalakis AD, Yu-Wai-Man C, Lamprou DA. Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment. Drug Delivery and Translational Research. 2025. doi:10.1007/s13346-024-01589-8
BibTeX
@article{Paleel2025,
author = {Paleel, Fathima and Qin, Mengqi and Tagalakis, Aristides D and Yu-Wai-Man, Cynthia and Lamprou, Dimitrios A},
title = {Manufacturing and characterisation of 3D-printed sustained-release Timolol implants for glaucoma treatment},
journal = {Drug Delivery and Translational Research},
year = {2025},
doi = {10.1007/s13346-024-01589-8}
}
EUVIMED